The Challenge of Assessing Remission and Relapse in ANCA Kidney Disease.
作者信息
Brix Silke R
机构信息
Renal, Transplantation and Urology Unit, Manchester University Hospitals NHS Foundation Trust, and Division of Cell Matrix Biology and Regenerative Medicine, University of Manchester, Manchester, United Kingdom.
出版信息
J Am Soc Nephrol. 2024 Apr 1;35(4):395-397. doi: 10.1681/ASN.0000000000000331. Epub 2024 Mar 13.
Abstract
摘要
相似文献
1
The Challenge of Assessing Remission and Relapse in ANCA Kidney Disease.
J Am Soc Nephrol. 2024 Apr 1;35(4):395-397. doi: 10.1681/ASN.0000000000000331. Epub 2024 Mar 13.
2
Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Nephrol Dial Transplant. 2016 Sep;31(9):1453-9. doi: 10.1093/ndt/gfw211. Epub 2016 May 30.
3
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
Ann Rheum Dis. 2023 Feb;82(2):253-261. doi: 10.1136/ard-2022-222479. Epub 2022 Aug 16.
4
Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
Front Immunol. 2020 Sep 3;11:2053. doi: 10.3389/fimmu.2020.02053. eCollection 2020.
5
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
Arthritis Rheumatol. 2016 Jul;68(7):1700-10. doi: 10.1002/art.39637.
6
Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
Intern Med. 2020 Dec 15;59(24):3187-3193. doi: 10.2169/internalmedicine.4731-20. Epub 2020 Aug 12.
7
Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1021-1028. doi: 10.2215/CJN.11801018. Epub 2019 Jun 28.
8
Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Arthritis Rheum. 2004 Apr 15;51(2):269-73. doi: 10.1002/art.20234.
9
The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
J Autoimmun. 2019 Dec;105:102302. doi: 10.1016/j.jaut.2019.07.001. Epub 2019 Jul 15.
10
An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis.
Clin Exp Immunol. 2024 Oct 16;218(2):120-135. doi: 10.1093/cei/uxae068.
引用本文的文献
1
ANCA-Associated Glomerulonephritis: Diagnosis and Therapy Proceedings of the Henry Shavelle Lectureship.
Glomerular Dis. 2024 Dec 2;5(1):26-47. doi: 10.1159/000542925. eCollection 2025 Jan-Dec.
本文引用的文献
1
Urinary CD4 + T Cells Predict Renal Relapse in ANCA-Associated Vasculitis.
J Am Soc Nephrol. 2024 Apr 1;35(4):483-494. doi: 10.1681/ASN.0000000000000311. Epub 2024 Jan 17.
2
The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials.
J Am Soc Nephrol. 2024 Mar 1;35(3):335-346. doi: 10.1681/ASN.0000000000000274. Epub 2023 Dec 12.
3
Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
Kidney Int. 2023 Jun;103(6):1144-1155. doi: 10.1016/j.kint.2023.02.029. Epub 2023 Mar 20.
4
Next-Generation Morphometry for pathomics-data mining in histopathology.
Nat Commun. 2023 Jan 28;14(1):470. doi: 10.1038/s41467-023-36173-0.
5
The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis.
J Am Soc Nephrol. 2021 Nov;32(11):2920-2932. doi: 10.1681/ASN.2021030382. Epub 2021 Sep 13.
6
Integrated multi-omics approaches to improve classification of chronic kidney disease.
Nat Rev Nephrol. 2020 Nov;16(11):657-668. doi: 10.1038/s41581-020-0286-5. Epub 2020 May 18.
7
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25.
8
Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.
Nat Rev Rheumatol. 2017 Nov;13(11):683-692. doi: 10.1038/nrrheum.2017.140. Epub 2017 Sep 14.
9
Urinary Soluble CD163 in Active Renal Vasculitis.
J Am Soc Nephrol. 2016 Sep;27(9):2906-16. doi: 10.1681/ASN.2015050511. Epub 2016 Mar 3.
10
CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN.
J Am Soc Nephrol. 2015 Sep;26(9):2105-17. doi: 10.1681/ASN.2014040407. Epub 2015 Mar 11.
Zotero 插件